Investing.com - Cellectar Biosciences (NASDAQ: CLRB) reported third quarter EPS of $-0.3800, $0.06 better than the analyst estimate of $-0.4425. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Cellectar Biosciences's stock price closed at $2.4000. It is up 31.8700% in the last 3 months and up 26.9800% in the last 12 months.
Cellectar Biosciences saw 2 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Cellectar Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Cellectar Biosciences's Financial Health score is "weak performance".
Check out Cellectar Biosciences's recent earnings performance, and Cellectar Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar